Amgen, Arris, Pharmacia & Upjohn deal

ARRS restructured its agreement with AMGN to develop small molecule therapeutics that mimic the activity of erythropoietin. The 1993 agreement, which was up for renewal in August of this year, is now renewable in February 1997. ARRS said it is expanding its program to develop mimetics for G-CSF and thrombopoietin (TPO) based on progress in the EPO work. ...